Regulation of hepatic lipid metabolism
AMPK phosphorylates and inactivates a number of metabolic enzymes
involved in lipid metabolism in order to maintain liver energy status. AMPK
coordinates the changes in the hepatic lipid metabolism and, so, regulates the
partitioning of fatty acids between oxidative and biosynthetic pathways.
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase) and acetyl
CoA carboxylase (ACC), key enzymes in cholesterol and fatty acid synthesis
respectively, were the first enzymes shown to be phosphorylated and inactivated
by AMPK (Corton
et al., 1994, Henin et al., 1995).
Although the action of AMPK is achieved by rapid and direct phosphorylation of
these enzymes, long-term effects have also been clearly demonstrated on gene
expression. AMPK activation by AICAR or by the use of adenovirus-mediated
overexpression of a constitutively active form of the a2 catalytic subunit (AMPKa2-CA)
inhibits glycolytic and lipogenic gene expression (Foretz
et al., 2005, Leclerc et al., 2001, Woods et al., 2000, Foretz et al., 1998,
Leclerc et al., 1998),
preserving glucose for ATP-producing pathways rather than for lipid synthesis.
Of note, AMPK activation reduces expression of sterol
regulatory element-binding protein-1c (SREBP1c) (Zhou
et al., 2001, Foretz et al., 2005) and carbohydrate response element–binding protein (ChREBP)
(Foretz
et al., 2005, Kawaguchi et al., 2002),
transcription factors playing a key role in the transcriptional
regulation of lipogenic and glycolytic genes by insulin and glucose,
respectively. In addition, it has been also reported that AMPK directly
phosphorylates ChREBP and modulates its DNA binding activity (Kawaguchi
et al., 2002).
Polyunsaturated fatty acids (PUFAs) are known to repress glycolytic and
lipogenic gene expression and raised the question about a role of AMPK in
mediating the effect of PUFAs on gene transcription. To address this point, we
investigated the effect of PUFAs in mice lacking AMPKa1/a2 catalytic subunits in the liver (AMPKa1a2LS-/-). In
the absence of hepatic AMPK, PUFAs continue to inhibit glycolytic and lipogenic
gene expression indicating the existence of AMPK-independent mechanism(s) (Viollet
et al., 2006).
In the cholesterol synthesis pathway,
AMPK blocks the conversion of HMG-CoA to mevalonate. One could expect
detrimental effect on cholesterol homeostasis when AMPK activity is altered. In
total and liver-specific AMPKa2 KO
mice, plasma levels for total and HDL cholesterol are not statistically
different compared to controls but have a tendency to be higher (Andreelli
et al., 2006, Viollet et al., 2003). This
suggested that remaining a1 subunit
activity in AMPKa2 KO mice is sufficient to control
hepatic cholesterol synthesis and that HMG-CoA reductase is a target for both
catalytic isoforms of AMPK.
ACC is an important rate-controlling enzyme for the synthesis of
malonyl-CoA, which is both a critical precursor for biosynthesis of fatty acids
and a potent inhibitor of mitochondrial fatty acid oxidation via the allosteric
regulation of carnitine palmitoyltransferase-1 (CPT-1) which catalyzes the entry
of long-chain fatty acyl-CoA into mitochondria. Inhibition of ACC by AMPK leads
to a fall in malonyl-CoA content and a subsequent decrease in fatty acid
synthesis concomitantly with an increase in b-oxidation (Brusq
et al., 2006, Velasco et al., 1997).
Exposure of hepatocytes to AICAR also produces a strong stimulation of
long-chain fatty acid oxidation as a result of an increase in the rate of
ketogenesis and an inhibition of triacylglycerol synthesis via phosphorylation
of sn-glycerol-3-phosphate acyltransferase (GPAT) (Muoio
et al., 1999). In
addition, overexpression of AMPKa2-CA in
the liver increases plasma ketone bodies levels, a surrogate marker for hepatic
b-oxidation (Foretz
et al., 2005).
Interestingly, AMPK-induced ACC phosphorylation is impaired in hepatocytes
deleted of both catalytic subunit, contributing to increase intracellular
malonyl CoA levels and triglyceride (TG) accumulation in the liver (B. Viollet,
M. Foretz, unpublished results). Thus, these results indicate that AMPK
regulates cellular lipid metabolism in large part through stimulation of fatty
acid oxidation. However, recent studies showed that AMPK also stimulates a
previously unrecognized pathway that involves constitutive exocytosis of
lipoproteins (Puljak
et al., 2008). This
alternative pathway appears to be quantitatively important for intracellular
lipid homeostasis and may function in parallel with fatty acid oxidation to
regulate intracellular lipid content.
Post Comment
No comments